Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review.

Autor:	Sirbu CA; Neurology Department, Titu Maiorescu University, 040441 Bucharest, Romania.; Neurology, Carol Davila Central Military Emergency University Hospital, 010242 Bucharest, Romania., Dantes E; Department of Pneumology, Faculty of Medicine, Clinical Hospital of Pneumophtisiology, 'Ovidius' University of Constanta, 900527 Constanta, Romania., Plesa CF; Neurology Department, Titu Maiorescu University, 040441 Bucharest, Romania.; Neurology, Carol Davila Central Military Emergency University Hospital, 010242 Bucharest, Romania., Docu Axelerad A; Department of Neurology, Faculty of Medicine, Clinical Emergency Hospital 'St. Apostol Andrei', 'Ovidius' University of Constanta, 900527 Constanta, Romania., Ghinescu MC; Neurology Department, Titu Maiorescu University, 040441 Bucharest, Romania.
Jazyk:	angličtina
Zdroj:	Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2020 Apr 24; Vol. 56 (4). Date of Electronic Publication: 2020 Apr 24.
DOI:	10.3390/medicina56040202
Abstrakt:	In this paper, we reported on four cases of severe pulmonary active tuberculosis in patients with multiple sclerosis (MS) undergoing interferon beta-1b (IFNβ-1b) therapy. Disease-modifying therapies (DMTs) in MS may increase the risk of developing active tuberculosis (TB) due to their impact on cellular immunity. Screening for latent infection with Mycobacterium tuberculosis (LTBI) should be performed, not only for the newer DMTs (alemtuzumab, ocrelizumab) but also for IFNβ-1b, alongside better supervision of these patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu